Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Sponsor: National Cancer Institute (NCI)
A observational or N/A phase clinical study on Stage I Chronic Lymphocytic Leukemia and Stage II Chronic Lymphocytic Leukemia, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 69 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)PRIMARY OBJECTIVE: I. To determine whether progression free survival (PFS) is superior after therapy with bendamustine hydrochloride (bendamustine) in combination with rituximab, ibrutinib alone, or ibrutinib in combination with rituximab in patients age 65 or older with previously untreated chronic lymphocytic leukemia (CLL). SECONDARY OBJECTIVES: I. To determine 2-year PFS in each of the three treatment arms. II. To determine which treatment arm produces superior overall survival (OS). III. To determine the complete response (CR) rate, complete and nodular partial response (CR/nPR) rate, and overall response (PR+nPR+CR) rate (ORR) among the three treatment arms and compare these arms. IV. To determine the impact of minimal residual disease (MRD)-negative disease at time of CR documentation and at 2 years on PFS and OS in each of the treatment arms. V. To determine duration of response after each of the three treatments and compare these treatment arms. VI. To determine toxicity and tolerability of the three treatment regimens. VII. To determine response and PFS of patients initially on the bendamustine in combination with rituximab arm who cross over to ibrutinib. OTHER PRE-SPECIFIED OBJECTIVES: I. To determine whether baseline cytogenetic markers, Zap-70 methylation, IgVH mutational status, or select deoxyribonucleic acid (DNA) mutations predict...
PRIMARY OBJECTIVE:
I. To determine whether progression free survival (PFS) is superior after therapy with bendamustine hydrochloride (bendamustine) in combination with rituximab, ibrutinib alone, or ibrutinib in combination with rituximab in patients age 65 or older with previously untreated chronic lymphocytic leukemia (CLL).
SECONDARY OBJECTIVES:
I. To determine 2-year PFS in each of the three treatment arms. II. To determine which treatment arm produces superior overall survival (OS). III. To determine the complete response (CR) rate, complete and nodular partial response (CR/nPR) rate, and overall response (PR+nPR+CR) rate (ORR) among the three treatment arms and compare these arms.
IV. To determine the impact of minimal residual disease (MRD)-negative disease at time of CR documentation and at 2 years on PFS and OS in each of the treatment arms.
V. To determine duration of response after each of the three treatments and compare these treatment arms.
VI. To determine toxicity and tolerability of the three treatment regimens. VII. To determine response and PFS of patients initially on the bendamustine in combination with rituximab arm who cross over to ibrutinib.
OTHER PRE-SPECIFIED OBJECTIVES:
I. To determine whether baseline cytogenetic markers, Zap-70 methylation, IgVH mutational status, or select deoxyribonucleic acid (DNA) mutations predict outcomes or time to response in these three arms.
II. To determine whether local fluorescence in situ hybridization (FISH) results for del(11q22.3) and del(17p13.1) are consistent with central analysis.
III. To determine whether baseline micro ribonucleic acid (RNA) and gene expression markers are correlated with clinical outcomes of interest (e.g. progression-free and alive at 2 years versus not), as well as to explore changes in microRNA expression from baseline to post-treatment time points, with a focus on those with persistent lymphocytosis and relapse.
IV. To determine whether eradication of MRD predicts longer duration of response with standard therapy and ibrutinib-based regimens.
V. To describe the baseline functional status, comorbid medical conditions, and number of medications of older CLL patients who meet criteria for therapy.
VI. To determine how functional status changes with therapy using baseline to 3-month evaluation and end-of-study/2-year evaluation; to determine whether this change is different among the treatment groups.
VII. To determine whether geriatric assessment variables known to be associated with chemotherapy toxicity in other disease groups can also predict therapy-associated toxicity in the CLL population.
VIII. To assess whether the FCGR3A polymorphism (rs396991) is correlated with depth of response (MRD status) to ibrutinib plus rituximab after 6 cycles, with secondary endpoints CR rate, rapidity of response, and progression-free survival (PFS).
IX. To assess whether C1QA polymorphism (rs172378) is correlated with MRD status, CR rate, rapidity of response, and PFS.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive rituximab intravenously (IV) on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
ARM II: Patients receive ibrutinib orally (PO) daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo bone marrow aspiration and biopsy, blood sample collection, and computed tomography (CT) throughout the study.
After completion of study treatment, patients are followed up every 6 months for up to 10 years.
Status Flow
Change History
69 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE3 → None
-
Mar 2026 — May 2026 [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 64 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Feb 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether rituximab with bendamustine hydrochloride may work better than rituximab and ibrutinib or ibrutinib alone in treating chronic lymphocytic leukemia.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .